BidaskClub lowered shares of Orthofix International N.V. (NASDAQ:OFIX) from a strong-buy rating to a buy rating in a research note released on Tuesday.

Other equities research analysts have also recently issued reports about the company. BTIG Research initiated coverage on Orthofix International N.V. in a research note on Wednesday, June 21st. They set a buy rating and a $52.00 price objective on the stock. Langenberg & Company reissued a buy rating and set a $53.25 price objective on shares of Orthofix International N.V. in a research note on Wednesday, June 14th. Ladenburg Thalmann Financial Services initiated coverage on Orthofix International N.V. in a research note on Wednesday, June 14th. They set a buy rating and a $53.25 price objective on the stock. SunTrust Banks, Inc. initiated coverage on Orthofix International N.V. in a research note on Tuesday, May 23rd. They set a buy rating and a $49.00 price objective on the stock. Finally, Zacks Investment Research raised Orthofix International N.V. from a sell rating to a hold rating in a research note on Thursday, July 6th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $51.30.

Orthofix International N.V. (OFIX) traded down 1.21% during trading on Tuesday, reaching $44.26. The company had a trading volume of 66,266 shares. The firm’s 50 day moving average is $45.58 and its 200 day moving average is $40.27. Orthofix International N.V. has a one year low of $32.51 and a one year high of $48.25. The company’s market capitalization is $798.63 million.

Orthofix International N.V. (NASDAQ:OFIX) last issued its quarterly earnings data on Thursday, May 4th. The medical device company reported $0.27 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.27. Orthofix International N.V. had a positive return on equity of 10.03% and a negative net margin of 0.82%. The company had revenue of $102.70 million for the quarter, compared to analysts’ expectations of $97.17 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities research analysts predict that Orthofix International N.V. will post $1.53 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Orthofix International N.V. (NASDAQ:OFIX) Rating Lowered to Buy at BidaskClub” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/orthofix-international-n-v-nasdaqofix-rating-lowered-to-buy-at-bidaskclub/1461699.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OFIX. Systematic Financial Management LP boosted its position in Orthofix International N.V. by 0.6% in the first quarter. Systematic Financial Management LP now owns 44,310 shares of the medical device company’s stock worth $1,690,000 after buying an additional 260 shares in the last quarter. American International Group Inc. boosted its position in Orthofix International N.V. by 7.1% in the first quarter. American International Group Inc. now owns 10,783 shares of the medical device company’s stock worth $411,000 after buying an additional 717 shares in the last quarter. Gabelli Funds LLC boosted its position in Orthofix International N.V. by 0.3% in the first quarter. Gabelli Funds LLC now owns 291,450 shares of the medical device company’s stock worth $11,119,000 after buying an additional 1,000 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its position in Orthofix International N.V. by 14.4% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 9,753 shares of the medical device company’s stock worth $372,000 after buying an additional 1,228 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its position in Orthofix International N.V. by 79.3% in the second quarter. State of Alaska Department of Revenue now owns 3,551 shares of the medical device company’s stock worth $165,000 after buying an additional 1,571 shares in the last quarter. 97.31% of the stock is currently owned by hedge funds and other institutional investors.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.